舒尼替尼用于治疗晚期肾细胞癌的临床分析(1)
摘 要：目的 研究晚期肾细胞癌患者应用舒尼替尼进行治疗的临床效果，为今后的治疗提供参考依据。方法 我院2015年10月～2016年10月共收治运用舒尼替尼治疗的晚期肾细胞癌患者36例，用药过程中如患者出现药物耐受力差的现象，则改注射为口服用药。了解分析患者在治疗期间的临床资料，观察舒尼替尼运用在治疗过程中具体用量、疗效及不良反应。结果 舒尼替尼用于治疗晚期肾细胞癌的有效控制率为88.88%。不良反应主要有手足综合征、高血压、困顿乏力、口腔粘膜炎、骨髓抑制以及食欲减退等，在调整药物用量后，患者基本可以忍受。结论 应用舒尼替尼治疗晚期肾细胞癌患者，疾病控制效果较为显著，治疗过程安全可靠，由于用药所引发的不良反应患者表示可以忍受，应用舒尼替尼治疗后，患者有望延长存活期，缓解疾病痛苦。
关键词：舒尼替尼；晚期肾细胞癌；不良反应
中图分类号：R737.11 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.06.043
, 百拇医药
文章编号：1006-1959(2018)06-0128-02
Clinical Analysis of Sunitinib in the Treatment of Advanced Renal Cell Carcinoma
WANG Guo-fu
(Department of Oncology，Jiamusi Central Hospital，Jiamusi 154002，Heilongjiang，China )
Abstract：Objective To study the clinical effect of sunitinib in patients with advanced renal cell carcinoma.Methods A total of 36 patients with advanced renal cell carcinoma treated with sunitinib were treated in our hospital from October 2015 to October 2016.In the course of medication，if the patient experienced poor drug tolerance，the injection was changed to oral administration.Understand the clinical data of the patients during the analysis and observe the specific dosage，efficacy and adverse reactions of sunitinib during the treatment.Results The effective control rate of sunitinib in the treatment of advanced renal cell carcinoma was 88.88%.Adverse reactions mainly include hand-foot syndrome，high blood pressure，fatigue，oral mucositis，myelosuppression，and loss of appetite.After adjusting the amount of medication，patients can basically tolerate it.Conclusion Patients with advanced renal cell carcinoma were treated with sulnitinib.The disease control effect was significant，and the treatment process was safe and reliable.Because the patients with adverse reactions caused by the use of drugs indicated that they could tolerate it，the patients treated with sulnitinib were treated with sunitinib.The patient is expected to prolong his survival and relieve the pain of the disease.
, 百拇医药
Key words：Sunitinib；Advanced renal cell carcinoma；Adverse reactions
腎脏恶性肿瘤中肾细胞癌是最常见的一类，约有30%的患者在初步确诊时就伴随癌细胞转移，早期患者体内癌细胞转移概率也非常高，达到25%。对于肾癌的治疗而言，由于放射治疗对于肾细胞癌的治疗作用不明显，因此传统治疗中常常应用白介素2及干扰素治疗，但是传统治疗的有效率一般低于20%，癌细胞转移率以及患者生存率也较低[1]。舒尼替尼类药物主要是通过对人体内酪氨酸激酶的受体进行抑制，从而有效的阻止肿瘤长大并阻止肿瘤血管的生长[2]。本文对于我院收治的晚期肾细胞癌患者应用舒尼替尼进行合理治疗，观察记录患者临床资料和治疗效果，为今后的治疗提供参考和依据。
1资料与方法
1.1一般资料 佳木斯市中心医院2015年10月～2016年10月共收治运用舒尼替尼治疗的经过病理学证实的晚期肾细胞癌患者36例，本研究通过我院医学伦理委员会审核。纳入及排除标准：患者及家属均签署研究知情同意书；在进行研究前4周以上未服用抗免疫类药物，不存在高血压等慢性疾病，不存在明显的骨骼、血液、内脏损伤，无精神障碍及语言表达能力困难。其中男29例，女7例，年龄33～72岁，平均年龄(48.32±6.57)岁，体重48～69 kg，平均体重(54.15±6.78)kg；所有患者均为未经过治疗的晚期肾细胞癌患者，14例患者为肺部转移，8例患者为骨转移，4例患者为脑转移，2例患者为肝转移，2例患者为肾床转移，1例患者为腹膜淋巴结转移，1例患者为甲状腺转移。, 百拇医药(王国富)
关键词：舒尼替尼；晚期肾细胞癌；不良反应
中图分类号：R737.11 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.06.043
, 百拇医药
文章编号：1006-1959(2018)06-0128-02
Clinical Analysis of Sunitinib in the Treatment of Advanced Renal Cell Carcinoma
WANG Guo-fu
(Department of Oncology，Jiamusi Central Hospital，Jiamusi 154002，Heilongjiang，China )
Abstract：Objective To study the clinical effect of sunitinib in patients with advanced renal cell carcinoma.Methods A total of 36 patients with advanced renal cell carcinoma treated with sunitinib were treated in our hospital from October 2015 to October 2016.In the course of medication，if the patient experienced poor drug tolerance，the injection was changed to oral administration.Understand the clinical data of the patients during the analysis and observe the specific dosage，efficacy and adverse reactions of sunitinib during the treatment.Results The effective control rate of sunitinib in the treatment of advanced renal cell carcinoma was 88.88%.Adverse reactions mainly include hand-foot syndrome，high blood pressure，fatigue，oral mucositis，myelosuppression，and loss of appetite.After adjusting the amount of medication，patients can basically tolerate it.Conclusion Patients with advanced renal cell carcinoma were treated with sulnitinib.The disease control effect was significant，and the treatment process was safe and reliable.Because the patients with adverse reactions caused by the use of drugs indicated that they could tolerate it，the patients treated with sulnitinib were treated with sunitinib.The patient is expected to prolong his survival and relieve the pain of the disease.
, 百拇医药
Key words：Sunitinib；Advanced renal cell carcinoma；Adverse reactions
腎脏恶性肿瘤中肾细胞癌是最常见的一类，约有30%的患者在初步确诊时就伴随癌细胞转移，早期患者体内癌细胞转移概率也非常高，达到25%。对于肾癌的治疗而言，由于放射治疗对于肾细胞癌的治疗作用不明显，因此传统治疗中常常应用白介素2及干扰素治疗，但是传统治疗的有效率一般低于20%，癌细胞转移率以及患者生存率也较低[1]。舒尼替尼类药物主要是通过对人体内酪氨酸激酶的受体进行抑制，从而有效的阻止肿瘤长大并阻止肿瘤血管的生长[2]。本文对于我院收治的晚期肾细胞癌患者应用舒尼替尼进行合理治疗，观察记录患者临床资料和治疗效果，为今后的治疗提供参考和依据。
1资料与方法
1.1一般资料 佳木斯市中心医院2015年10月～2016年10月共收治运用舒尼替尼治疗的经过病理学证实的晚期肾细胞癌患者36例，本研究通过我院医学伦理委员会审核。纳入及排除标准：患者及家属均签署研究知情同意书；在进行研究前4周以上未服用抗免疫类药物，不存在高血压等慢性疾病，不存在明显的骨骼、血液、内脏损伤，无精神障碍及语言表达能力困难。其中男29例，女7例，年龄33～72岁，平均年龄(48.32±6.57)岁，体重48～69 kg，平均体重(54.15±6.78)kg；所有患者均为未经过治疗的晚期肾细胞癌患者，14例患者为肺部转移，8例患者为骨转移，4例患者为脑转移，2例患者为肝转移，2例患者为肾床转移，1例患者为腹膜淋巴结转移，1例患者为甲状腺转移。, 百拇医药(王国富)